Distinguished in Marginal Zone Lymphoma (MZL)

Dr. Basem M. William

Hematology Oncology | Hospital Medicine | Transplant Surgery
Ohiohealth Corporation
500 Thomas Ln, 2e, 
Columbus, OH 
Accepting New Patients
Distinguished in Marginal Zone Lymphoma (MZL)
Ohiohealth Corporation
500 Thomas Ln, 2e, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Basem William is a Hematologist Oncology specialist and a Hospital Medicine provider in Columbus, Ohio. Dr. William is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. William is currently accepting new patients.

His clinical research consists of co-authoring 78 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Marginal Zone Lymphoma (MZL).

Specialties
Hematology Oncology
Hospital Medicine
Transplant Surgery
Licenses
Hospitalist in ME
Hospital Affiliations
Grant Medical Center
Marion General Hospital
Riverside Methodist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

OHIOHEALTH CORPORATION
500 Thomas Ln, 2e, Columbus, OH 43214

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
Enrollment Status: Completed
Publish Date: July 25, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab Vedotin, Lenalidomide
Study Phase: Phase 2
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: May 14, 2025
Intervention Type: Procedure, Drug
Study Drugs: Carmustine, Cytarabine, Etoposide, Melphalan, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 1/Phase 2
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 1
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Withdrawn
Publish Date: December 09, 2021
Intervention Type: Drug
Study Drug: Avatrombopag
Study Phase: Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

78 Total Publications

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study.
Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study.
Journal: Transplantation
Published: June 23, 2025
Similar Doctors
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Beth A. Christian
Hematology | Hematology Oncology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Beth A. Christian
Hematology | Hematology Oncology

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
 (5.6 miles away)
614-366-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Beth Christian is a Hematologist and a Hematologist Oncology provider in Dublin, Ohio. Dr. Christian is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Christian is currently accepting new patients.

Advanced in Marginal Zone Lymphoma (MZL)
Dr. Daljeet J. Singh
Hematology Oncology | Hematology | Oncology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Daljeet J. Singh
Hematology Oncology | Hematology | Oncology

Mercy Health Physicians Springfield Specialty Care LLC

900 Scioto St, Suite 1, 
Urbana, OH 
 (37.3 miles away)
937-717-4884
Languages Spoken:
English, Punjabi, Spanish
See accepted insurances
Accepting New Patients

Daljeet Singh is a Hematologist Oncology specialist and a Hematologist in Urbana, Ohio. Dr. Singh is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Familial Colorectal Cancer, Small Lymphocytic Lymphoma (SLL), Breast Cancer, and Paget Disease of the Breast. Dr. Singh is currently accepting new patients.

Advanced in Marginal Zone Lymphoma (MZL)
Dr. Aruna C. Gowda
Hematology Oncology | Hematology | Oncology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Aruna C. Gowda
Hematology Oncology | Hematology | Oncology

Licking Memorial Professional Corporation

1320 W Main St, 
Newark, OH 
 (30.8 miles away)
220-564-4000
Languages Spoken:
English, Hindi, Kannada
See accepted insurances
Accepting New Patients

Aruna Gowda is a Hematologist Oncology specialist and a Hematologist in Newark, Ohio. Dr. Gowda is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Thrombocytopenia. Dr. Gowda is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. William's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 14 Advanced Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile